BAM Argentina

From Argentina, to the world.

Driving innovation in Clinical Research

Team of clinical trials experts providing accurate data and high-quality care.

20+ years of experience

We work with the most important regulatory authorities in the world: ANMAT (Argentina), FDA (United States) and EMA (Europe).

Find out how to be part of our studies here.

30+ clinical trials

Patient recruitment has a limited time window. Apply today to be included as soon as the next available trial begins.

FDA, EMA & ANMAT

Advanced-stage studies that have already passed all safety tests and now compare efficacy to match or exceed the best treatment available.

Clinical trials

Why take part in a clinical trial?

Taking part in a clinical trial is a process that demands the utmost responsibility and care. Every study is designed under strict international protocols to guarantee patient safety and the scientific validity of the results. Before it begins, all potential risks and benefits are assessed in detail, and the guidelines set by regulatory authorities such as ANMAT, FDA and EMA are followed, ensuring that every step meets the highest quality standards.

The experience and professionalism of the team running the study are decisive factors. At our institution we have a group of specialized physicians and healthcare professionals with extensive experience in clinical research. Every team member is trained to safeguard the safety, well-being and rights of each patient, working with dedication and commitment at every stage of the trial.

Studies conducted

92 %

Projects completed

71 %

Targets exceeded

Management and professionalism that increase the speed and the consistency of results:

SPONSOR: GSK
STUDY: B WELL 1 / 202009
CONDITION: Chronic hepatitis B treated with nucleoside/nucleotide analogues
DRUG:
STATUS: Recruiting
ENROLLMENT TARGET:
EXCEEDED: 3

SPONSOR: Eli Lilly
STUDY: J3L-MC-EZEF / ACCLAIM-Lp(a)
CONDITION: Atherosclerotic cardiovascular disease
DRUG:
STATUS: Recruiting
ENROLLMENT TARGET: 4
EXCEEDED: 5

SPONSOR: Eli Lilly
STUDY: ACHIEVE-4 / J2A-MC-GZGS
CONDITION: Type 2 diabetes and obesity or overweight with increased cardiovascular risk
DRUG: LY3502970 administered once daily compared with insulin glargine
STATUS: Recruitment closed
ENROLLMENT TARGET: Expected enrollment
EXCEEDED: 11

SPONSOR: ROCHE
STUDY: LUCERNE
CONDITION: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
DRUG: FARICIMAB
STATUS: COMPLETED
ENROLLMENT TARGET: 5 PATIENTS
ACHIEVED: 5 PATIENTS

SPONSOR: ROCHE
STUDY: AVONELLE
CONDITION: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
DRUG: FARICIMAB (LUCERNE extension)
STATUS: ONGOING
ENROLLMENT TARGET: 4 PATIENTS
ACHIEVED: ✅ 4 PATIENTS

SPONSOR: ALVOTECH
STUDY: AV706-GL-C01
CONDITION: WET NEOVASCULAR MACULAR DEGENERATION
DRUG: AVT06 compared with EU-EYLEA
STATUS: ONGOING
ENROLLMENT TARGET: 3 PATIENTS
EXCEEDED: ✅ 5 PATIENTS

SPONSOR: OPTHEA
STUDY: COAST
CONDITION: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
DRUG: OPT-302
STATUS: ONGOING / OPEN RECRUITMENT
ENROLLMENT TARGET: 5 PATIENTS
ACHIEVED: ✅ 4 PATIENTS

SPONSOR: IVERIC BIO
STUDY: ISEE_2008
CONDITION: GEOGRAPHIC ATROPHY
DRUG: ZIMURA
STATUS: COMPLETED
ENROLLMENT TARGET: 3 PATIENTS
ACHIEVED: ✅ 3 PATIENTS

SPONSOR: ROCHE
STUDY: SANDCAT
CONDITION: UVEITIC MACULAR EDEMA
DRUG: RO07200220
STATUS: ONGOING / OPEN RECRUITMENT
ENROLLMENT TARGET: 5 PATIENTS

SPONSOR: ROCHE
STUDY: ALLUVIUM
CONDITION: DIABETIC MACULAR EDEMA
DRUG: RO7200220
STATUS: ONGOING
ENROLLMENT TARGET: 5 PATIENTS
EXCEEDED: ✅ 10 PATIENTS

SPONSOR: OCUDYNE, INC
STUDY: OC-1901AR
CONDITION: AGE-RELATED MACULAR DEGENERATION
DRUG: SURGICAL INTERVENTION PROCEDURES
STATUS: ONGOING / OPEN RECRUITMENT
EXCEEDED: ✅ 4 PATIENTS

SPONSOR: Roche
STUDY: SATRAGO / GP44467
CONDITION: Thyroid eye disease
DRUG:
STATUS: Recruiting
ENROLLMENT TARGET:
ENROLLED: 2

SPONSOR: Novo Nordisk
STUDY: REIMAGINE 4
CONDITION: Assessment of the efficacy and safety of cagrilintide and semaglutide 2.4 mg
DRUG:
STATUS: Recruiting
ENROLLMENT TARGET:
EXCEEDED: 15

SPONSOR: OTX
STUDY: OTX-TKI-2023-AMD-301
CONDITION: Neovascular age-related macular degeneration
DRUG:
STATUS: Recruiting
ENROLLMENT TARGET:
ENROLLED:

SPONSOR: SANTEN
STUDY: LUMINA
CONDITION: ACTIVE INFECTIOUS POSTERIOR SEGMENT UVEITIS
DRUG: DE-109 440 µg
STATUS: COMPLETED
ENROLLMENT TARGET: 3 PATIENTS
EXCEEDED: ✅ 6 PATIENTS

SPONSOR: NOVARTIS
STUDY: KESTREL
CONDITION: DIABETIC MACULAR EDEMA
DRUG: BROLUCIZUMAB versus AFLIBERCEPT
STATUS: COMPLETED
ENROLLMENT TARGET: 10 PATIENTS
EXCEEDED: ✅ 24 PATIENTS

SPONSOR: APELLIS
STUDY: APL-303
CONDITION: GEOGRAPHIC ATROPHY SECONDARY TO AMD
DRUG: PEGCETACOPLAN
STATUS: COMPLETED
ENROLLMENT TARGET: 6 PATIENTS
EXCEEDED: ✅ 11 PATIENTS

SPONSOR: APELLIS
STUDY: APL2-305-GALE
CONDITION: GEOGRAPHIC ATROPHY SECONDARY TO AMD
DRUG: PEGCETACOPLAN (APL-303 extension)
STATUS: ONGOING
ENROLLMENT TARGET: 6 PATIENTS
EXCEEDED: ✅ 9 PATIENTS

SPONSOR: ALVOTECH
STUDY: AV706-GL-C01
CONDITION: WET NEOVASCULAR MACULAR DEGENERATION
DRUG: AVT06 compared with EU-EYLEA
STATUS: ONGOING
ENROLLMENT TARGET: 3 PATIENTS
EXCEEDED: ✅ 5 PATIENTS

SPONSOR: NOVARTIS
STUDY: CONDOR
CONDITION: BROLUCIZUMAB 6 mg compared with laser photocoagulation
DRUG: BROLUCIZUMAB 6 mg
STATUS: ONGOING
ENROLLMENT TARGET: 10 PATIENTS
EXCEEDED: ✅ 11 PATIENTS

SPONSOR: ROCHE
STUDY: BALATON
CONDITION: MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION
DRUG: FARICIMAB
STATUS: COMPLETED
ENROLLMENT TARGET: 4 PATIENTS
EXCEEDED: ✅ 8 PATIENTS

SPONSOR: ROCHE
STUDY: COMINO
CONDITION: MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION
DRUG: FARICIMAB
STATUS: COMPLETED
ENROLLMENT TARGET: 4 PATIENTS
EXCEEDED: ✅ 13 PATIENTS

SPONSOR: ROCHE
STUDY: BARDENAS
CONDITION: DIABETIC MACULAR EDEMA
DRUG: RO7200220 in combination with RANIBIZUMAB
STATUS: ONGOING
ENROLLMENT TARGET: 5 PATIENTS
EXCEEDED: ✅ 6 PATIENTS

Contact

These are our contact channels.
We will be in touch with you very soon!

981 Arenales, 4th Floor, Buenos Aires, Argentina

info@bamsite.com.ar

+54 9 11 5565 6846